Upcoming Events
Log In
Pricing
Free Trial

Benign and Malignant Breast Calcifications, Dr. Omar Nemer (7-16-26)

HIDE
PrevNext

0:02

Hello, and welcome to Noon Conference hosted by Modality.

0:06

Noon Conference connects global radiology community through free live

0:10

educational webinars that are accessible for all and is an opportunity to learn

0:14

alongside top radiologists from around the world.

0:17

Today, we are honored to welcome Dr.

0:19

Omar Nemer

0:21

for a lecture entitled Benign and Malignant

0:24

Breast Calcifications.

0:27

Dr. Omar Nemer completed his radiology residency and breast imaging

0:31

fellowship at the University of Rochester Strong Memorial Hospital

0:35

in Rochester, New York. He returned to his birthplace of Northeast

0:39

Ohio, where he now serves as an associate program director of

0:43

diagnostic radiology at Case Western Reserve University

0:46

Hospitals. At the end of the lecture, please join Dr.

0:49

Nemer in a Q&A session where he will address questions you may have on today's

0:53

topic.

0:54

Please remember to use the Q&A feature to submit your questions so we can get to as

0:57

many as we can before our time is up.

1:00

With that, we are ready to begin today's lecture. Dr.

1:02

Nemer, please take it from here.

1:05

Hello, everyone. Thank you guys so much for joining me today.

1:08

I'm Omar Nemer, and I'm thrilled to be presenting you guys with a talk on

1:12

benign and malignant breast calcifications.

1:15

Calcifications remain one of the most challenging findings we encounter in breast

1:19

imaging. Although many of them represent a benign physiologic

1:22

process, others are the earliest and sometimes only

1:26

manifestation of breast cancer. Today, we'll review a practical

1:30

framework for interpreting calcifications using the updated

1:33

BI-RADS 6 lexicon while discussing the pathology and

1:37

clinical reasoning that guide management.

1:39

All cases used in this presentation are directly from our PAC system, unless

1:43

otherwise stated. No stock images were used in the making of this

1:47

presentation. There are a few AI-generated images, which I

1:51

will direct you guys to.

1:53

Please excuse the grayscale nature of this.

1:57

Color is often a luxury not afforded to us working in mammography.

2:03

I have nothing to disclose at this time.

2:07

And so what are exactly breast calcifications?

2:10

They're radiodense calcium deposits primarily composed of calcium

2:13

hydroxyapatite and calcium oxalate that occur in the breast

2:17

for a variety of benign and more concerning reasons.

2:22

So when do we identify calcifications?

2:25

They're initially detected on screening mammography in most cases.

2:30

After identifying the calcifications on a screening mammogram, the first thing we

2:34

need to ask ourselves is, are these clearly benign?

2:37

We'll discuss all the possible examples of typically benign

2:40

calcifications, for example, vascular and skin

2:43

calcifications. Next, if they're not clearly benign,

2:47

are they present on a prior mammogram?

2:50

If so, are they increasing, or are they stable?

2:53

If they're not clearly benign and have not been stable for ideally two

2:57

years, further workup should be recommended.

3:00

Things change a bit when we're working with a baseline exam, which we'll

3:04

discuss in more detail as well.

3:07

Finally, we should describe the location of the calcifications using the quadrant

3:10

of the breast in which they're seen and their depth and provide a

3:14

BI-RADS 0 assessment and recommend additional imaging with

3:17

diagnostic mammography. Annotation of the images is also

3:21

crucial to help future colleagues identify the exact area of

3:24

concern.

3:29

After we've identified the calcifications, the next step will almost

3:32

always be diagnostic mammography with spot magnification views in the

3:36

craniocaudal and mediolateral projections.

3:40

We need the mediolateral projection instead of an MLO view,

3:43

mediolateral oblique view, as these will most often

3:47

be targeted on either a CC or ML

3:51

projection. MLO biopsies are possible

3:55

but much more difficult.

3:58

For anyone interested in the underlying physics of a spot magnification view,

4:02

these are performed using an air gap for magnification with a tiny focal

4:05

spot for optimal resolution. Spot magnification

4:09

views should always be performed with attention to ensure there's no

4:12

motion, as it can significantly blur the morphology of the

4:15

calcifications. We then describe the location, the

4:19

morphology, the distribution, and the extent of the calcifications,

4:23

including measurements when appropriate for future extent of disease

4:26

discussions if the biopsies prove malignant.

4:31

Results for a diagnostic mammogram for calcifications can only be as follows.

4:36

BI-RADS 2 for benign calcifications, BI-RADS 3 for

4:39

probably benign calcifications, BI-RADS 4 for suspicious

4:43

calcifications, which would be anything greater than a 2%

4:46

chance of malignancy, and BI-RADS 5 for highly

4:50

suspicious calcifications or anything greater than a 95% chance of

4:54

malignancy.

4:58

This is an AI-generated slide provided to me by one of my

5:02

residents who did a fantastic job with this.

5:06

Before we discuss the morphology of calcifications, I'd like to discuss the

5:09

distribution.

5:11

Distribution describes how calcifications are arranged within the breast while the

5:15

morphology describes what each individual calcification looks like.

5:19

Morphology establishes the baseline level of suspicion, and the distribution

5:23

tells us whether the process appears random or follows the anatomy of the ductal

5:27

system.

5:28

Starting on the left, diffuse calcifications are scattered throughout a large

5:32

portion of the breast without a focal or ductal pattern.

5:35

When they are bilateral, symmetric, and have benign morphology, they're usually

5:39

benign. However, diffuse distribution does not override

5:43

suspicious morphology.

5:45

Regional calcifications occupy a relatively large volume,

5:49

generally greater than two centimeters, but do not conform to a duct or a

5:53

single breast segment. Malignancy is less likely than with

5:57

a linear or segmental pattern, although unilateral regional calcifications

6:01

with suspicious morphology should still require biopsy.

6:05

Grouped calcifications are concentrated in a small area of less than two

6:09

centimeters. Group distribution is not automatically suspicious

6:13

but often requires comparison with prior studies.

6:17

The key point is that grouping concentrates our attention,

6:21

but morphology determines what we'll do next.

6:24

Linear calcifications are arranged along a line, sometimes with branching.

6:29

This raises concern that the calcifications are depositing within a duct.

6:33

Suspicion increases considerably when the individual

6:36

calcifications are fine linear or fine linear branching.

6:39

And finally, segmental calcifications form a triangular or

6:43

wedge-shaped distribution pointing towards the nipple corresponding to a

6:47

duct in its branches within a breast segment.

6:50

When suspicious calcification morphology follows this pattern, the finding is

6:53

almost always associated with malignancy.

6:56

The take-home message is that distribution is not an absolute benign to malignant

7:00

scale. It's better understood as a risk modifier.

7:03

The final assessment should integrate morphology, distribution,

7:07

laterality, interval change, and associated findings such as a

7:11

mass or architectural distortion.

7:15

The first set of typically benign calcifications we'll discuss is skin

7:19

calcifications. These are often described as loose and centered, which

7:23

can overlap with other benign morphologies.

7:26

Although their appearance is often pathognomonic, these are even easier to

7:29

localize to the skin with the use of tomosynthesis rather than in the days of

7:33

traditional 2D mammography.

7:36

The classic teaching is that if calcifications are in the first or last five

7:39

slices of a tomosynthesis stack, they're likely to be within the skin.

7:43

I do find this to be a bit of an oversimplification.

7:46

Using the natural skin landmarks, such as observing the pores of the

7:50

skin or the skin vasculature, as we can see on our right-hand

7:54

image,

7:55

is a much more accurate depiction of whether they'll be

7:59

in the skin. The reason is that on the detector side of the

8:03

imaging, for example, on a craniocaudal view, the inferior aspect of the

8:07

breast would be against the detector.

8:09

The last image in the stack towards the caudal aspect of the

8:13

breast will always be at the skin. However, on the tube side of the

8:17

image, in this case in the superior aspect of the breast, the

8:20

tomosynthesis units can't exactly determine the slice where the

8:24

breast ends. So oftentimes, you'll have several tomosynthesis

8:27

slices which appear outside of the skin on the tube side of the stack.

8:31

So although you may be only in slice 50 out of 65,

8:36

you may still be well within the skin if you can see landmarks that clearly

8:39

identify the skin, such as the pores.

8:42

This is also very important when assessing breast calcifications along the

8:46

curvature of the breast.

8:49

So let's say you're stuck in ancient times with 2D mammography, or you're not quite

8:53

certain if those calcifications are in the skin on tomosynthesis

8:56

images. What options do we have to prove it?

9:00

That's where an old technique called tangential magnification views come

9:04

in. An image is taken of the breast with an alphanumeric grid

9:08

placed over the expected location of the calcifications.

9:11

Using the alphanumeric grid, a BB is placed over the site of the

9:14

calcifications. The breast is then rotated so that the BB is

9:18

tangential to the X-ray beam, and another image is taken.

9:22

If the calcifications are flush with the skin, you know they're skin calcs.

9:27

If the calcifications appear deeper, you know they're not.

9:30

There's one caveat. You need to be sure that you're on the correct side of the

9:33

breast. If the skin calcifications are inferior and you placed your BB

9:37

on the superior aspect of the breast, it's not going to work.

9:45

Next, let's discuss vascular calcifications.

9:47

These are often abbreviated BAC for breast arterial

9:50

calcifications, and they have their own grading system recently developed by

9:54

the Canadians from grade 0, meaning no vascular calcifications,

9:59

to grade 3, meaning severe or coarse vascular or tram track

10:02

calcifications affecting three or more vessels.

10:05

There's a little graph for us in the bottom right-hand corner.

10:09

There are many studies evaluating when we should be reporting these calcifications,

10:13

but generally, if you see moderate to severe calcifications in women under

10:17

60, it's worth reporting so that they can be assessed for cardiovascular risk

10:21

factors. There are even AI programs that have been developed or are

10:25

being developed to do this automatically, generating referrals to cardiology

10:29

for assessment.

10:33

Large rod-like calcifications, traditionally referred to as

10:37

secretory calcifications, are often associated with duct

10:40

ectasia or sequelae of plasma cell mastitis.

10:44

They're much more common in women over the age of 60, are often bilateral,

10:48

and follow a ductal distribution.

10:51

They often demonstrate branching as well.

10:54

Although these can be extremely easy to recognize, they can present some real

10:58

diagnostic dilemmas when initially forming, as they can be difficult to

11:01

distinguish from the highly suspicious fine linear branching pattern.

11:06

Seeing them develop bilaterally can help us distinguish them from their more

11:09

suspicious counterparts, although this is not a hard and fast rule as they can

11:13

still present unilaterally. Don't hesitate to recommend a biopsy

11:17

if you're not sure.

11:21

Coarse calcifications are now an extremely broad

11:24

category under the new BI-RADS atlas, now encompassing both

11:28

popcorn calcifications, which was a term traditionally used to describe

11:32

degenerating fibroadenomas, and dystrophic

11:35

calcifications, which are typically seen post-surgically.

11:40

This is one of the few changes regarding calcifications in BI-RADS 6.

11:45

These are large and conspicuous calcifications and are generally

11:48

greater than one millimeter and are dense and easily visualized.

11:52

They may be single or occur in clusters.

11:55

They're often associated with involuting fibroadenomas, fat

11:58

necrosis, prior surgery, trauma, or radiation therapy.

12:03

They have many different appearances, all of which we should recognize as benign.

12:07

They are not to be confused with coarse heterogeneous calcifications, which are

12:11

smaller and often vary in shape and size and will be discussed later

12:15

in detail.

12:19

Rim calcifications, sometimes referred to as eggshell or lucent

12:23

centered calcifications, are thin, benign calcifications that

12:27

appear as calcium deposited on the surface of a sphere.

12:30

They're often less than one millimeter in thickness when viewed on the

12:34

edge, and smooth in appearance.

12:37

These are often seen in fat necrosis, oil cysts, calcified

12:41

debris in ducts, or calcifications of cyst walls.

12:45

These often occur as sequelae to trauma, such as the example

12:48

provided here where a patient had a seatbelt injury from a motor vehicle

12:52

accident. The oil cysts can be seen traveling

12:56

horizontally down the breast in the expected pattern of the

12:59

seatbelt. The oil cysts and fat necrosis can sometimes be

13:03

difficult to diagnose on other modalities in breast imaging, such as MRI or

13:07

ultrasound. For example, at our institution, we perform what's called

13:11

fast breast MRIs, where we do not perform native T1

13:15

non-fat saturated sequences, making fat necrosis difficult to

13:18

distinguish from more concerning enhancement.

13:21

They can appear as shadowing masses on ultrasound as well.

13:24

If you suspect fat necrosis or oil cysts, mammography is always the

13:28

easiest modality to identify them and don't

13:31

hesitate to request additional mammographic imaging.

13:37

Layering calcifications are among the most satisfying imaging

13:41

diagnoses in mammography, in my opinion, due to their incredibly characteristic

13:45

appearance on spot magnification views.

13:48

These have been traditionally referred to as milk of calcium because their

13:51

appearance is a result of sedimented calcium layering into cysts and

13:55

acini. However, BI-RADS 6 makes clear that they do not

13:58

approve of any food-related nomenclature, waxing milk of

14:02

calcium and popcorn from our vocabulary.

14:05

On spot magnification CC views, they often appear as round and

14:09

smudgy. However, the key is that they change in appearance on lateral views

14:13

when gravity causes the calcium deposits to layer.

14:16

They form characteristic teacupping or crescent shapes on

14:19

mediolateral views, or sometimes just straight lines.

14:24

The key is that they have to change morphology on the orthogonal views.

14:29

Oftentimes, you will see diffuse layering calcifications, and some may

14:33

not layer. Be wary that suspicious calcifications can still

14:37

hide in a background of benign layering calcifications and

14:41

pay close attention that the vast majority of the calcifications are layering.

14:48

Round calcifications are one of the most common calcifications described on

14:52

diagnostic mammography. In the new BI-RADS atlas, round,

14:56

which was traditionally between 0.5 and one millimeter,

15:00

and punctate, which was traditionally round calcifications measuring less than

15:04

0.5 millimeters, have been lumped together due to the

15:07

impracticality of measuring individual calcifications.

15:11

Many of us have already been using them somewhat synonymously,

15:14

often reporting grouped round and punctate calcifications, so this is a

15:18

welcome simplification.

15:21

It is most important to assess the distribution and longitudinal

15:24

assessment of round calcifications.

15:28

Which brings us to BI-RADS 3. BI-RADS 3

15:32

is reserved for findings with a 2% or lower likelihood of

15:35

malignancy. For calcifications, the classic qualifying

15:39

finding is a single group of round calcifications discovered

15:43

on baseline mammography that has been evaluated with diagnostic

15:46

magnification views. These will be followed every six

15:50

months for two years to ensure that they remain stable, and the

15:54

18-month follow-up is often not necessary.

15:57

So it would be six months, six months, 12 months.

16:00

If any increase in the calcifications is visualized, these should be

16:03

biopsied.

16:06

Although this is the only true use case for BI-RADS 3 with

16:10

calcifications as defined by BI-RADS, I think anyone who's

16:13

engaged in breast imaging knows that this is often used much more

16:16

broadly. For example, in my own practice, I recently assigned a BI-RADS

16:21

3 to a case with regional amorphous calcifications that were likely

16:24

present on a prior exam, but so fine that it was nearly impossible to

16:28

tell. The key is to use your best judgment and try to assign

16:32

BI-RADS 3s as infrequently as possible.

16:35

The cost of three to four additional diagnostic mammograms can add

16:39

up extremely quickly for patients in cases where we could have just assigned a

16:43

BI-RADS 2. And in cases where a BI-RADS 3 was assigned and the

16:47

calcifications do increase and end up demonstrating malignancy, it's

16:51

important to know that it's still considered a false negative exam by BI-RADS

16:55

criteria and will not protect you from litigation if a BI-RADS 3 was

16:58

inappropriately assigned.

17:04

Here we have another image generated by

17:07

AI, but it provides a great

17:11

demonstration of the textbook baseline for the

17:15

old BI-RADS books and the new modern literature range

17:18

for concerning calcifications that can occur in the

17:22

breast.

17:24

For amorphous calcifications, it was traditionally thought to be a positive

17:27

predictive value of around 20%, which is now felt to be much lower.

17:32

For coarse heterogeneous calcifications, it was traditionally

17:36

thought to be around 15%, but now can be seen up to

17:40

30%.

17:42

Fine pleomorphic calcifications were only seen with a

17:46

positive predictive value of up to 30%, now up to almost

17:49

80%. And fine linear branching calcifications

17:54

have always thought to be suspicious, but are now seen to be

17:57

malignant in almost 100% of cases in some studies.

18:04

So let's begin with amorphous calcifications.

18:06

Amorphous calcifications are small and hazy and by definition cannot be

18:10

assigned a particular shape.

18:12

I know we're trying to wipe food analogies, but I often refer to their appearance

18:16

as powdered sugar. They encompass a wide variety of calcifications

18:20

overall, and therefore the distribution of calcifications and longitudinal

18:24

assessment as to whether they were new or increasing becomes extremely important.

18:29

I tried to use several different images to give a good demonstration of the

18:32

appearance of amorphous calcifications, and this is unfortunately the best I can

18:36

do. By their nature, they're going to be extremely difficult to

18:39

accurately visualize without full-scale mammography.

18:44

The distinction between coarse

18:48

heterogeneous calcifications and benign coarse calcifications is often

18:52

easy to describe in a book or lecture, but becomes very difficult in

18:56

practice.

18:57

By definition, compared to coarse calcifications, which are often over

19:01

two to three millimeters, coarse heterogeneous calcifications are

19:05

often half to a millimeter in size and are

19:09

irregular in shape. Distribution again becomes extremely

19:13

important in assessing concern, with grouped, linear,

19:16

segmental, or new and increasing calcifications warranting

19:20

biopsy.

19:21

It's not always cut and dry, unfortunately.

19:24

For example, in the case I've displayed here, although these calcifications

19:28

are diffuse, they ended up demonstrating LCIS and invasive lobular

19:31

carcinoma.

19:37

Fine pleomorphic calcifications are among the most suspicious morphology

19:41

and should almost always be immediately recognized and biopsied,

19:45

regardless of distribution. They consist of calcifications in

19:48

varying shapes and sizes, often referred to as a

19:52

dot-dash pattern like Morse code.

19:55

We can see the plethora of different morphologies within the grouping

19:59

demonstrated on the left in the CC and ML projections,

20:03

showing both linear, round, and irregular

20:06

calcifications.

20:08

Biopsy of these calcifications yielded ductal carcinoma in situ.

20:17

Fine linear and fine linear branching calcifications appear as thin,

20:21

linear, irregular calcifications which may be discontinuous and are

20:25

typically less than 0.5 millimeters in caliber.

20:28

Excuse me. Their appearance suggests filling of the lumen of the

20:32

ducts by breast cancer.

20:34

Again, these should almost always be immediately

20:38

recognized and biopsied, regardless of distribution, although they are

20:42

often in linear segmental distributions.

20:50

So that concludes the didactic portion of this lecture.

20:54

The remaining portion of the lecture is a few cases that I'd like to present to you

20:58

guys just to challenge what we've learned

21:01

and see if we have any questions about it.

21:08

And also, I apologize in advance. Again, without

21:11

full-field mammography monitors, a lot of these calcifications are

21:15

going to be difficult to identify.

21:18

So for case one, we have a screening mammogram, and we can

21:22

see calcifications kind of scattered around,

21:25

but there is a grouping of calcifications that we can see in the

21:29

central medial right breast at middle depth that appear

21:33

different than the rest of the calcifications.

21:35

Additional spot magnification views were recommended.

21:41

On additional spot magnification views, it's a bit difficult to see,

21:46

but there are linear branching calcifications

21:50

that are occurring in a Y-shaped pattern.

21:57

These were subsequently biopsied and demonstrated DCIS.

22:08

For our second patient,

22:10

calcifications were identified in the lateral central left

22:13

breast at middle depth.

22:17

On additional spot magnification views, we see that these calcifications

22:21

clearly layer on the orthogonal view and appear

22:25

smudgy and round on the CC

22:28

view. I'm sorry, I'm using my cursor in the wrong area.

22:31

Smudgy and round on the CC view

22:34

and demonstrate teacupping or layering on the ML view,

22:38

and so these are clearly benign milk of calcium.

22:49

For our third case, we have a grouping of calcifications that was

22:53

identified on screening mammography.

22:55

It's a bit harder to see. We're not really particularly interested in this dense

22:59

coarse calcification, but this small grouping of calcifications behind

23:03

it.

23:07

On additional spot magnification views, we see amorphous

23:11

grouped calcifications

23:14

corresponding to the calcifications initially seen on mammography.

23:18

These were biopsied and demonstrated atypia.

23:22

Atypical ductal hyperplasia, to be specific.

23:32

And here's a more zoomed-in photo to see that amorphous

23:36

morphology.

23:39

There's a few coarse calcifications also contained within

23:41

those.

23:45

But we always look at the most suspicious morphology of the

23:48

calcifications provided.

23:55

I'm not sure if we're able to go into the chat, but this is an Aunt

23:59

Minnie case, and I'm curious if anyone knows what this

24:02

is. But we see extensive rim

24:06

calcifications,

24:12

oil cysts,

24:18

Bourneville Pringle. I actually don't know what that is.

24:23

Siliconoma, oil cysts, fat injections. Yes.

24:26

So it's actually

24:28

pathognomonic for free silicone injections.

24:32

This is something that was done in

24:35

Way back in the '70s, '80s, as an alternative to breast

24:39

augmentation.

24:41

And this patient actually presented to me,

24:44

it was a transgender male transitioning to female

24:48

patient

24:50

that had had free silicone injections to

24:53

increase his breast size and had gotten them on

24:57

the black market. I had never seen a case

25:02

in real life before this, but it was extremely interesting.

25:05

I felt terrible for the patient. He was having, or she, excuse me, she was having

25:09

so much pain

25:11

in both the breasts and the axillas from

25:14

the silicone traveling into the lymph nodes and

25:18

causing silicone granulomas.

25:22

So silicone would be injected directly into the breast tissue without

25:25

being contained in a shell and would disperse into the breast and surrounding

25:29

tissues. This could cause many long-term issues due to the formation of silicone

25:33

granulomas, and the lymph nodes become hard and painful.

25:36

Although the free silicone is not linked to a direct increase in breast

25:39

cancer, it does make future screening extremely difficult.

25:43

Like free silicone elsewhere, this generates a characteristic snow storm

25:47

appearance on the ultrasound.

25:56

For our next case, we have grouped calcifications

26:00

that were identified in the superior, slightly medial left breast

26:04

on screening mammography.

26:11

On additional spot magnification views, we see both

26:15

coarse heterogeneous and possibly some linear branching

26:18

patterns of these calcifications.

26:22

These ended up being DCIS with a

26:26

microinvasive component.

26:32

Here we just see a typical demonstration of large

26:36

coarse benign calcifications for which no additional

26:40

imaging is necessary.

26:47

So

26:49

this case was initially identified on screening

26:53

mammogram and spot magnification views

26:56

demonstrated some coarse and round grouped calcifications

27:00

in the upper outer left breast.

27:02

They were initially given an assessment of a BI-RADS 3 appropriately,

27:07

and the patient returned for follow-up.

27:11

On follow-up imaging, we can see that there's an increase in those

27:15

calcifications.

27:19

This was subsequently assigned a BI-RADS 4 and

27:23

biopsied and demonstrated ductal carcinoma in

27:25

situ. This is a great example of how

27:29

longitudinal management can be helpful in assessment.

27:37

Next, we have a screening mammogram of the left breast demonstrating

27:40

calcifications in the upper outer left breast at

27:44

anterior depth,

27:46

for which additional spot magnification views were recommended.

27:53

On additional spot magnification views, we see a clear linear

27:57

branching pattern and a segmental distribution indicating a

28:00

highly suspicious finding.

28:05

These were biopsied and demonstrated

28:07

DCIS. I think an interesting

28:12

note that I can make here too is there's a lot of

28:15

discussion around when we should perform just one biopsy of the

28:19

calcifications versus two biopsies to demark the

28:23

anterior and posterior extent of disease and calcifications.

28:28

There's no set hard and fast rules.

28:31

Our institution uses about four centimeters of

28:34

calcifications.

28:37

If there's more than four centimeters of calcifications, it may be more worthwhile

28:42

to do two biopsies, one at the anterior and one at the

28:46

posterior aspect of the calcifications.

28:49

This can make things easier to localize in the future and can help determine the

28:53

extent of disease.

28:55

Anytime you have a large grouping of calcifications and there's more than one

28:59

different type of morphology of calcifications that you see within those

29:03

groupings,

29:04

you should biopsy multiple, excuse me, you should biopsy each

29:08

of the different morphologies to make sure that we're

29:11

not getting a benign result at one where one might be

29:15

malignant.

29:20

For this next case,

29:22

the calcifications are difficult to identify here just because of the quality of

29:25

the images, but there are calcifications in the upper inner left

29:29

breast at posterior depth.

29:33

On additional spot magnification views,

29:36

we see grouped kind of coarse heterogeneous calcifications,

29:40

and on the CC view, they appear to be in a linear pattern.

29:45

These were suspicious and biopsied and demonstrated

29:49

DCIS.

29:54

And finally, for our last case, we have calcifications that were

29:58

identified in the upper outer left breast at

30:02

middle to posterior depth,

30:04

for which additional spot magnification views were performed.

30:09

And I apologize, I lost the spot magnification views on those,

30:14

but they did demonstrate calcifications in a segmental pattern, which is what

30:18

I was trying to demonstrate here, and you can see how it's kind of a

30:21

pizza pie shape

30:24

projecting from the nipple.

30:28

Although we're not using food terminology anymore, I know, I'm sorry.

30:32

And these were highly suspicious and demonstrated DCIS with

30:35

an invasive component

30:39

And last, I just have our little frowny face of calcifications

30:43

I biopsied because they were upset with me.

30:47

No, I'm just kidding. These were benign. Thank you guys so much.

30:52

I'll take any questions.

30:57

Awesome. Thank you so much. I do see one question in the Q&A feature, and just want

31:01

to direct all other questions over there if anyone else has any other

31:05

ones.

31:06

Thank you so much. "Is the spot view on the CC projection

31:10

necessary to evaluate microcalcifications, or is a true lateral

31:14

view sufficient?" Spot CC views are absolutely

31:18

necessary in evaluating microcalcifications.

31:21

Seeing the calcifications in two orthogonal planes

31:24

makes a world of difference in assessing the morphology

31:28

and the distribution of these calcifications.

31:31

For example,

31:33

for these calcifications, I don't have the spot magnification views,

31:37

but they didn't appear quite as segmental or

31:40

concerning in the CC view, but they definitely appear

31:44

segmental and concerning on the ML view.

31:47

And it's always necessary to have them both.

31:52

"Can I recommend any good articles regarding this?"

31:56

I would recommend looking through the BI-RADS atlas.

31:59

I have not seen any good review articles recently on

32:03

calcifications, but mostly probably because I wasn't looking, and I

32:07

apologize for that. "To what extent of the

32:11

calcifications in your practice to suggest mastectomy?" So that is

32:15

a great question.

32:19

That is determined by the surgeon and the patient.

32:23

We can suggest a mastectomy, but it is an

32:26

extremely fluid conversation, depending on the size of

32:30

the breast, especially. So let's say we have about four

32:34

centimeters of calcifications. I believe the traditional thinking was greater

32:38

than five centimeters or so of disease, you should do a

32:41

mastectomy. But, if a woman has extremely

32:45

large breasts, five centimeters of disease may

32:49

not be that much disease in relation to the size of her

32:53

breast. They may be able to do a lumpectomy, and you might not even

32:56

notice a change in the size of the breast.

33:00

So there is actually no hard and fast rule regarding when a

33:03

mastectomy needs to be performed, and that will always just be a

33:07

discussion between the surgeon and the patient.

33:10

We have a great relationship with our surgeons here at University Hospital, and

33:13

we often are in discussions all the time with them as to

33:17

whether we feel the patient may need a mastectomy based on the imaging

33:21

features. There's a lot that goes into that in terms of,

33:25

can we appropriately bracket this in two planes

33:30

in order to remove the extent of the disease?

33:33

And sometimes it's not possible. Sometimes there's just such a

33:37

wide margin of disease, it's not just

33:41

localized to this kind of segmental pattern, that you would have to

33:45

do a whole quadrantectomy, in which case you should just probably do a

33:48

mastectomy. And sometimes it's an extremely long length of

33:52

disease, but it's very narrow and

33:56

can be done with bracketing. So there's really just no hard and fast rule

34:00

there.

34:01

And I'm going to go through these in order.

34:04

I'm going to start with the Q&A box.

34:07

"Amorphous versus round and punctate is confusing.

34:09

Can you please clarify?" So if you can see, and I completely agree by the

34:13

way,

34:15

if you can see a well-defined

34:19

borders to these calcifications, oftentimes you can call

34:23

them round and punctate.

34:25

The amorphous calcifications, it's very hard to describe because

34:29

they, by definition, don't have a shape. They're indistinct.

34:33

You can't really identify an exact shape.

34:36

They just kind of look like you sprinkled something on the breast

34:39

there. A lot of times, they're extremely difficult to identify on the screening

34:43

mammography itself, and sometimes they don't even appear until you get those

34:47

spot magnification views.

34:49

But that is a great question, and I wish I had a better answer for that.

34:54

"We biopsy calcifications scored M3 and over

34:58

in the UK."

35:00

I sincerely apologize. I don't know what the M3

35:04

scoring is in reference to, if you don't mind clarifying

35:07

that.

35:09

"Do we do ultrasound-guided biopsy of suspicious calcifications?"

35:14

Typically not.

35:16

If there's an associated mass or architectural

35:19

distortion or ultrasound finding that is seen in

35:22

conjunction with the calcifications, absolutely, you can

35:27

biopsy those on ultrasound. And oftentimes what I do in those cases

35:31

is I'll use a vacuum-assisted device, and then I will X-ray the

35:35

specimen to ensure I got some calcifications in that specimen.

35:39

But isolated calcifications, I will practically never

35:43

biopsy by ultrasound alone. They should always be done

35:47

using stereotactic biopsy.

35:51

"Do you think follow-up should be done in a case of even slightly

35:55

suspicious calcification in the case you showed us, which turned out to

35:59

be malignant?"

36:02

We could have just gone straight to biopsy on that case.

36:05

It was a baseline, and I believe she did have calcifications

36:09

scattered throughout both breasts, and so those didn't look

36:12

as concerning in the larger clinical picture, but it would not have

36:16

been inappropriate to biopsy in that situation.

36:20

With calcifications, it's one of the things in

36:23

mammography that always surprises me.

36:26

There are so many times where looking at the diagnostic

36:30

imaging, I've been certain that calcifications would come out benign,

36:34

and they've demonstrated some sort of atypical or early

36:37

malignant pathology, and that's just kind of how it goes, unfortunately.

36:41

We follow the BI-RADS atlas and do the best we can in those

36:45

cases.

36:48

What information do surgeons ask for before performing a mastectomy,

36:52

specifically regarding the size of the microcalcification

36:55

areas? That's particularly the first one is, what is the

36:59

extent? And you want to identify that extent in all three

37:03

planes, if possible.

37:05

Transverse, craniocaudal, and,

37:10

excuse me, why am I blanking? APTR and CC,

37:13

sorry. On top of that,

37:16

it also depends if the surgeon is interested in getting an MRI for

37:20

extent of disease. The MRIs for extent of disease in

37:24

the case of calcifications is-- or excuse me, in the case of DCIS

37:28

specifically, which is typically from calcifications, is somewhat

37:31

controversial, just because

37:35

early-grade DCIS does not have to enhance on

37:38

MRI,

37:40

and so sometimes it may not be the best form of

37:44

extent of disease management. However, that's pretty rare in my

37:48

practice. Almost always, if we see DCIS on a mammogram

37:52

that was biopsied and we get an MRI, it almost always enhances.

37:56

The other things that we're looking at when we're evaluating the extent of disease,

38:00

is there any involvement of the chest wall?

38:04

How close does it come to the chest wall or pectoralis muscle?

38:07

How close does it come to the skin? And then how close does it come to the nipple?

38:11

And that can even be important in evaluating if a patient

38:15

needs a nipple-sparing versus radical mastectomy.

38:19

Excuse me, not radical, but non-nipple-sparing mastectomy.

38:24

And so if those calcifications are within one to two centimeters, and I think

38:28

the criteria has changed of the surgeons as to what the exact

38:32

measurement is within the nipple.

38:34

As long as it's not closer

38:38

than one to two centimeters from the nipple, oftentimes they can spare the

38:42

nipple.

38:45

M3 is the same as BI-RADS 3. Thank you so much.

38:47

So let me go back to your questions.

38:49

We biopsy calcifications scored

38:52

BI-RADS 3 and over in the UK. Our practice is to follow anything

38:56

that's given a BI-RADS 3. If we feel that they need to

39:00

be biopsied, if we feel the calcifications need to be biopsied, we go

39:04

directly to what you might consider an M4 or a BI-RADS 4 for

39:07

us.

39:10

Is abscess still given a BI-RADS

39:14

4a? I'm not 100% sure.

39:19

I've seen kind of varying thoughts on that.

39:22

Typically, I give, if I'm 100% certain it's an abscess, I give it a

39:26

BI-RADS 2 every time for benign, and I recommend drainage and

39:29

antibiotics. But if it's not certain that it's an

39:33

abscess, if you're not 100% certain, then I do assign a BI-RADS 4,

39:38

and then I request follow-up imaging after

39:42

treatment to see if that area has resolved.

39:46

If that area has not resolved, I keep it a four, and I recommend

39:50

an ultrasound-guided biopsy, and if it has

39:53

resolved,

39:55

then I just change it to a two. We're very lucky in our

39:58

practice. We have our clinical practitioners that see patients for us

40:02

directly when they're having their imaging if needed, and so

40:06

it's much easier to come up with a game plan

40:11

when the patient's being seen right there in clinic for their abscess,

40:15

just as they're getting their imaging.

40:17

And then, I'm sorry, I'm going to scroll back up

40:20

here.

40:26

In the BI-RADS 3 case, would it have helped to perform

40:29

contrast-enhanced mammography?

40:33

So we only recommend contrast-enhanced mammography in very

40:37

specific situations. Typically, for high-risk

40:40

screening for individuals who can't have an MRI,

40:46

or for extent of disease and evaluation for patients who can't undergo

40:50

MRI. In calcifications, I've never

40:54

seen contrast-enhanced mammography

40:57

ordered for the assessment of calcifications.

40:59

I don't think that there are any studies demonstrating

41:03

a benefit to that, but someone else may be more knowledgeable about that.

41:09

Will AI and improved workstation monitors eventually decrease

41:13

the amount of follow-ups on additional mammographic imaging?

41:17

I certainly hope so. I'm not sure how

41:20

much better the monitors can really get.

41:24

But AI, I think, will help

41:28

in reducing the number of callbacks, to be clear, because I

41:32

think,

41:33

in the AI studies that I've read, one of the biggest things is they

41:37

can help identify a negative case.

41:40

So if the AI identifies nothing of concern on the

41:44

case, there's a very high predictive value that it's

41:48

correct.

41:49

But it has a really hard time identifying, or

41:53

not a really hard time, but it has a harder time identifying positive things.

41:57

So if you do have things that marked, it does not mean that that thing is

42:00

suspicious.

42:02

You still need to review, if you have an AI program.

42:05

We do not have an AI program established with our mammography yet.

42:09

But if you do, you should kind of treat it like CAD.

42:12

It's directing your attention to certain areas, and

42:16

you are going to evaluate with your knowledge and expertise,

42:20

what you see at that area. Does fine-needle

42:24

aspiration biopsy have a role, or is it just core biopsy for more

42:28

samples? We do not perform fine-needle aspirations,

42:33

typically, only in very select cases.

42:36

Almost always, we're performing core biopsies.

42:39

I think that's the standard

42:42

for most institutions these days.

42:48

Does contrast-enhanced mammography show microcalcifications?

42:51

Absolutely it does, because-

42:55

Typically, 2D images are created which will demonstrate the

42:58

microcalcifications, as well as the contrast-enhanced images.

43:03

They have to do both to create a subtraction in the same way that

43:06

you would do pre- and post-contrast MRIs.

43:10

And so, yes, you would see the microcalcifications.

43:12

You would not see them in good detail because you need those spot magnification

43:16

views. And so let's say you had a patient being screened with

43:19

contrast-enhanced mammography.

43:22

I believe, and I'm not 100% certain on this, but I'm almost certain, the

43:25

recommendation is that they still get a typical screening mammogram, whether it's

43:29

2D or tomosynthesis. So the calcifications are probably going to be much better

43:33

identified there anyways,

43:36

but you would still be able to see them on the CEM.

43:42

Microcalcifications with lucent center should almost always be a BI-RADS

43:46

2. Sometimes in very rare circumstances,

43:50

depending on a distribution and whether they're increasing, it's hard to say that

43:54

that's 100%, but almost always lucent

43:58

centered calcifications will be a BI-RADS 2 benign.

44:01

I'm going to move over to the chat because I think people asked some questions in

44:05

here, too.

44:10

Okay. I think we answered that one already.

44:16

Do you advise MR for suspicious calcifications?

44:19

No, I would recommend that you never advise MR for

44:23

suspicious calcifications. I think I briefly touched on it, but

44:27

low-grade DCIS does not necessarily enhance on MRI, and

44:31

therefore you're actually doing the patient a disservice by recommending

44:35

an MRI for calcifications. The recommendation should always

44:39

be diagnostic mammography with spot magnification views.

44:43

It's actually something that we've struggled with in our

44:47

practice recently, is we will recall patients from

44:51

mammography, for additional mammographic and sonographic

44:54

views, and their providers

44:59

just kind of expect that MRI is the best test, and so

45:02

sometimes they'll kind of ignore those recommendations and just skip straight to

45:06

MRI.

45:08

And it is extremely challenging,

45:13

because a lot of times the best test would've just been that

45:17

diagnostic mammography and ultrasound, and then you're kind

45:20

of stuck in this position of backtracking, trying to

45:24

associate the findings that you initially saw on the

45:27

screening mammogram,

45:31

and it's just something that I would never recommend.

45:36

And let's see. BI-RADS 3, how concerning is

45:40

it? Is there a possibility of it turning into cancer, especially if the

45:44

patient's breast showed dense breast tissue?

45:47

So our studies within breast imaging show

45:50

that you shouldn't really be giving a BI-RADS 2 unless it's less than a 2% chance

45:54

of breast cancer. So you have to think it's between a zero and 2% chance that it'll

45:58

develop into cancer if it's a BI-RADS 3.

46:02

Sometimes patients will request to just have those biopsied because they

46:06

don't want to sit and be anxious for two years, and I totally respect

46:09

that. The fact that they have

46:13

dense breast tissue shouldn't play a factor in the

46:17

calcifications themselves, although dense breast tissue is

46:20

independently a risk factor for developing breast cancer.

46:25

Is vacuum biopsy acceptable to biopsy segmental

46:29

calc or stereo always? If there's an

46:32

associated ultrasound finding, such as a mass

46:36

on the ultrasound, it's totally fine to do it under

46:39

ultrasound.

46:41

If you can clearly see the calcifications under

46:45

ultrasound and you want to attempt an ultrasound-guided biopsy because the patient

46:48

can't have a stereotactic biopsy, that may not be

46:52

inappropriate. But if you have the capability of doing a stereotactic biopsy and

46:56

you're looking at calcifications and there's no associated ultrasound finding

46:59

besides those

47:02

fine echogenic foci on the ultrasound, I

47:05

would say just always do a stereotactic biopsy.

47:09

That would be the recommendation.

47:15

What would be the number of calcifications needed in

47:19

a new cluster for biopsy? Can we biopsy if the number is less than five?

47:23

I'm not 100% sure about the number that you would need in a

47:27

new cluster for biopsy. I've done it in

47:31

cases of three or less that were oriented in a linear pattern, and

47:35

they came out DCIS. So I don't think there's an exact

47:38

number. Obviously, if it's one singular calcification,

47:43

I think

47:44

that would be an easy one not to biopsy,

47:46

but anything like two, three, or more, it's not

47:50

unreasonable if the morphology is suspicious or the distribution is

47:54

suspicious.

47:58

How many calcifications in the sample need to be

48:01

representative for calcifications?

48:04

So I assume that's

48:05

in respect to if you're doing a stereotactic

48:09

biopsy and you image the specimen,

48:13

how many calcifications do we need to see within that specimen?

48:18

Sometimes I've only gotten one or two calcifications in

48:22

what looked like a larger grouping, and I've been able to make a diagnosis, and

48:26

sometimes I've gotten more than that, and they haven't identified

48:30

any calcifications in the pathology sample.

48:33

I think the real answer is just as many as you can get.

48:37

If you only have one or two, it's going to be much harder for that

48:41

pathologist to make a diagnosis. There's a chance that the slices that they cut

48:45

through your specimen don't contain those one or two calcifications.

48:49

So really, the answer is just get as many as you can

48:53

without causing undue harm to the patient,

48:56

and hope for the best.

49:00

"What BI-RADS score do you assign if you have MRI lesion

49:03

BI-RADS 2, but no mammography was

49:07

performed as the patient does not want?"

49:10

It's kind of a decision based on you and your group

49:14

and your institution.

49:18

You're supposed to really just recommend the

49:22

BI-RADS score based on the imaging that you're looking at.

49:25

So if it's a negative MRI, you should just give it a

49:29

BI-RADS 2 or BI-RADS 1, and then say, "This patient is

49:33

due for annual screening, and we recommend annual screening." Some patients just

49:37

won't do the screening, and I don't think it's appropriate to just keep giving them

49:41

zeros over and over again for every one of their exams.

49:45

There are patients who just can't undergo mammography due to certain

49:49

reasons. And so, you should just assign the BI-RADS

49:53

category based on the imaging that you're looking at, and then make that additional

49:56

recommendation. My tagline that I always use

50:00

is

50:04

basically, "MRI is not a

50:09

replacement for mammography, and mammography should still be performed

50:13

if possible."

50:14

Because it's not a replacement for mammography, because of exactly what we're

50:17

talking about in regards to low-grade DCIS, which can

50:21

be diagnosed mammographically, but not on MRI.

50:27

"Can MRI be done to look for the extent of

50:31

invasive disease in biopsy-proven

50:35

B5b microcalcifications?" I'm so sorry.

50:38

I don't know what B5b is. But absolutely, MRI can be

50:42

done to evaluate the extent of disease

50:46

in any microcalcifications that came back cancerous.

50:51

So even if you do a biopsy and the patient

50:55

has atypia on pathology,

50:59

that patient's now high risk, and so they qualify for

51:03

screening MRI,

51:05

even if it's not necessarily a, quote-unquote, "extent of disease

51:09

MRI." So you can definitely, with any sort of

51:13

positive finding on a biopsy of calcifications, you can

51:16

justify an MRI in some regards. Is it always the best choice?

51:20

Maybe, and maybe not.

51:23

In cases of atypia or high-risk lesions that

51:26

we're finding from calcifications, it typically is a very good

51:30

choice to get additional screening with MRI because their risk is going to be so

51:34

high.

51:36

But

51:39

I lost my train of thought there. I apologize.

51:41

But

51:43

it can definitely be done to evaluate for extent of

51:46

disease.

51:51

And then let me see

51:54

if there's anything else here. "Post-operative

51:58

scar with lucent center developing centrally

52:02

microcalcifications."

52:05

Post-operative scar with lucent center developing

52:09

centrally microcalcifications.

52:14

I think what you might be referring to in some cases would be

52:18

fat necrosis occurring at a post-operative scar.

52:21

That's where a lot of times we see the oil cysts forming with lucent

52:25

centers.

52:26

And actually, I had a case which I did not include in my

52:30

presentation today, but I think I actually have it

52:34

open on my computer somewhere if I look really quickly.

52:39

Let me see real quick. But I did have a case where a patient had

52:43

lucent centered calcifications at a lumpectomy bed, and they developed new

52:47

calcifications

52:49

right in line with those lucent centered

52:51

calcifications. Those calcifications looked a little bit more coarse,

52:55

heterogeneous, amorphous. We biopsied them, and it did end up being a

52:59

recurrence. It's not always the case.

53:02

Sometimes it's just developing fat necrosis at a post-surgical

53:05

site. But you kind of have to just take all the factors into account.

53:10

If the patient had a lumpectomy because they had cancer that presented as

53:14

calcifications at that lumpectomy site, you need to

53:18

be very cautious about the calcifications that you're going to

53:21

follow or call benign as opposed to biopsy at that site, because there's a very

53:25

high risk of recurrence occurring as calcifications at that site.

53:29

Does that answer your question? I apologize.

53:31

I wasn't 100% sure what you're asking.

53:36

I'm always happy to take questions offline as well.

53:40

You are always welcome to email me at

53:42

omar.nemer@uhhospitals.org.

53:46

It was such a pleasure giving this talk for you all.

53:49

Thank you guys all for the words of encouragement.

53:52

I hope you guys enjoyed it. I hope you guys all learned something, and I really

53:55

appreciate you guys having me.

53:58

Awesome. Thank you for sharing that lecture with us today, Dr.

54:01

Nemer. Be sure to join us next week

54:05

on Thursday, July 23rd at 12:00 p.m., where

54:09

Dr. Suresh Mukherjee will deliver a lecture entitled "Emergency Head and

54:13

Neck: What You Need to Know in the Middle of the Night." You can register for that

54:17

at modality.com and follow us on social media for updates on future

54:20

noon conferences. Thanks again, and have a great day.

Report

Tags

Women's Health

Breast